. 2021 Jun 14;13(7):e08253. doi: 10.15252/emmm.201708253

Table 1.

Randomized phase III clinical trials of VEGF pathway inhibitors as adjuvant (Postoperative) cancer therapies.

Trials	Cancer Type	Arms	Results associated with VEGF Pathway Inhibition
NSABP C‐08 ^a AVANT*^b QUASAR2 ^c E5204 ^d	Colorectal cancer	Chemotherapy +/− bevacizumab	No DFS or OS benefit (*AVANT: worse OS with Bev)
BEATRICE ^e ECOG‐5103 ^f BETH ^g	Breast cancer	Chemotherapy +/− bevacizumab	No IDFS or OS benefit
AVAST‐M ^h	Melanoma	Observation vs. bevacizumab	DFI benefit, but no OS benefit
E1505 ⁱ	Non‐small‐cell lung carcinoma	Chemotherapies +/− bevacizumab	No DFS or OS benefit
STORM ^j	Hepatocellular carcinoma	Placebo vs. sorafenib	No RFS/DFS or OS benefit
ASSURE ^k S‐TRAC ^l	Renal cell carcinoma	Placebo vs. sunitinib	No DFS or OS benefit
ATLAS ^m	Renal cell carcinoma	Placebo vs. axitinib	No DFS benefit, except in highest risk sub‐population
PROTECT ⁿ ECOG‐ACRIN‐2810 ^o	Renal cell carcinoma	Placebo vs. pazopanib	No DFS benefit
SORCE ^p	Renal cell carcinoma	Placebo vs. sorafenib	No DFS or OS benefit

DFI, disease‐free interval; DFS, disease‐free survival; IDFS, invasive DFS; OS, overall survival; RFS, recurrence‐free survival.

^{^a}

Allegra et al (2013).

^{^b}

de Gramont et al (2012), André et al (2020).

^{^c}

Kerr et al (2016).

^{^d}

Benson et al (2016).

^{^e}

Cameron et al (2013).

^{^f}

Miller et al (2014, 2018).

^{^g}

Slamon et al, (2013).

^{^h}

Corrie et al (2014, 2017).

^ⁱ

Wakelee et al (2016, 2017).

^{^j}

Bruix et al (2014).

^{^k}

Haas et al (2016).

^{^l}

Ravaud et al (2016).

^{^m}

Gross‐Goupil et al (2018).

^ⁿ

Motzer et al (2017).

^{^o}

Appleman et al (2019).

^{^p}

Eisen et al (2020).